Altimmune, Inc. (ALT) Stock

About Altimmune, Inc.

Altimmune, Inc. is led by CEO Jerome Benedict Durso, employs 59 people, headquartered in US, publicly traded since 2017.

Altimmune, Inc. (ALT) stock trades at $2.12 with a market capitalization of $412.38M. The stock is valued at a negative price-to-earnings (P/E) ratio of -3.42, reflecting a net loss over the last twelve months, price-to-book of 1.04, price-to-sales of 16749.86. Over the past 52 weeks the stock has ranged between $2.08 and $6.44, and currently trades 67.1% below its 52-week high.

On profitability, Altimmune, Inc. generates a return on equity (ROE) of -31.41% (negative, reflecting a net loss), return on capital employed of -19.47%, a net profit margin of -2530.03%.

Altimmune, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Altimmune, Inc. reported revenue of $5.0M rising to $0, a change of -100.0% across 10 years. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-88.0M.

Operating margin went from -215.4% in 2016 to -230461.0% in 2025, a fall of 230245.6 percentage points. The most recent net margin is -2530.03%. On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-92.0M.

Borrowings rose from $1.0M to $36.0M, cash from operations was $-68.0M in the latest year, positive in 1 of the last 10.

Return on equity has averaged -51.1% over five years, and was -39.1% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Altimmune, Inc. (ALT) — frequently asked questions